Evidence map›Paper›PMID 40301039›Full record

ArticleInternal medicine (Tokyo, Japan)2025

Rare Case of Severe Pancreatitis Induced by Encorafenib and Cetuximab in BRAF V600E-Positive Colorectal Cancer.

Yu Miyakawa, Yuki Ishigaki, Nobumi Suzuki, Go Endo, Chisaki Suzumori, Takeshi Hayashi, Kenji Tamada, Takuma Iwata, Gota Fujisawa, Yoku Hayakawa and 2 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yu MiyakawaDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan.
Yuki IshigakiDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan.
Nobumi SuzukiDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan.
Go EndoDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan.
Chisaki SuzumoriDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan.
Takeshi HayashiDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan.
Kenji TamadaDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan.
Takuma IwataDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan.
Gota FujisawaDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan.
Yoku HayakawaDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan.
Narikazu BokuDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan.
Mitsuhiro FujishiroDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Doublet chemotherapy with encorafenib and cetuximab has demonstrated a survival benefit for BRAF V600E mutation-positive advanced colorectal cancer, which generally has a poor prognosis, as shown in the BEACON CRC trial. We encountered a case of rectal cancer with this mutation, complicated by grade 3 pancreatitis, one month after starting this doublet therapy. Despite aggressive treatment efforts, the pancreatitis led to duodenal ulcer perforation and a fatal intra-abdominal abscess. This case highlights pancreatitis as a rare, but severe, side effect of combination chemotherapy.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCarbamatesColorectal NeoplasmsPancreatitisProto-Oncogene Proteins B-rafRectal NeoplasmsSulfonamidesAgedCetuximabFatal OutcomeHumansMaleMiddle AgedMutationBRAF protein, humanCarbamatesCetuximabencorafenibProto-Oncogene Proteins B-rafSulfonamidesBEACONBRAF V600Ecetuximabencorafenibpancreatitis

Identifiers

PMID40301039
PMCPMC12702560

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.